ELQ-300 |
| Katalog-Nr.GC35974 |
ELQ-300 ist ein wirksames und oral bioverfÜgbares Antimalariamittel, das als Inhibitor der reduktiven (Qi)-Stelle des Cytochrom-bc1-Komplexes (cyt bc1) wirkt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1354745-52-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ELQ-300 is a potent and orally bioavailable antimalarial agent, acts as an inhibitor of the reductive (Qi) site of the cytochrome bc1 complex (cyt bc1)[1]. ELQ-300 sensitizes P. falciparum Dd2, Tm90-C2B, and D1 strains with IC50s of 6.6, 4.6 and 160 nM, respectively[1].
[1]. Stickles AM, et al. Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum. Antimicrob Agents Chemother. 2015 Apr;59(4):1977-82.
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *